ENTITY
MabPharm

MabPharm (2181 HK)

14
Analysis
Health CareChina
Mabpharm Limitied manufactures medical products. The Company produces cancer treatment drugs, immune diseases drugs, biosimilar drugs, and other products. Mabpharm markets its products throughout China.
more
Refresh
05 Aug 2019 11:11

HK IPO Analytics 1H2019: MS and CICC Stand Out

At the beginning of this year, we at Aequitas Research wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...

Logo
600 Views
Share
28 Jul 2019 13:24

🇨🇳🇭🇰 That Was The Week That Was • China/Hong Kong 22nd-27th July 2019 @Smartkarma

TW3 CHINA/HONG KONG 22-27 JUNEThis TW3 covers China and Hong Kong and is a companion to the North Asian TW3 published earlier today.  The weight of...

Logo
567 Views
Share
bullishTai Hing
13 Jun 2019 12:39

Tai Hing (太興) Trading Update - Edible

Tai Hing (6811 HK) raised US$96m at HK$3.00 per share, below the mid-point of its price range. We have covered the IPO in our previous two...

Share
bearishMabPharm
31 May 2019 12:24

MabPharm (迈博医药) Post-IPO Trading Update: Poor Debut for a Reason

MabPharm's IPO was priced near the low end and started trading today. We have highlighted in our earlier note that the company's product pipeline...

Logo
619 Views
Share
25 May 2019 01:51

ECM Weekly (25 May 2019) - ESR Cayman, Hansoh Pharma, Tai Hing, China East Edu, Haitong UniTrust

Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...

Share
x